Molnupiravir Armageddon

healthcare,

Molnupiravir Extends COVID-19 Viral Phase, Evidenced by the High Frequency of Rare and Dangerous Mutations in SARS-COV-2, preprint, 2021-12-20

Unexpected Mildness of Host-Induced Mutations in SARS-COV-2, preprint v2, (v1, 2021-12-08)

Treating a Pandemic Respiratory Disease with a Mutagen is a Doomsday Scenario, preprint, 2021-12-02

AMDAC used the decision-making process in authorization of Remdesivir (Remdeathivir) as the precedent for decision-making on Molnupiravir not knowing that Remdesivir is harmful, and its authorization was corrupt. Continue reading Molnupiravir Armageddon →

Molnupiravir Poisons Bone Marrow when it is Needed Most

healthcare, ,

7 days at 0.4x human dose (in dogs) is equivalent or exceeds 2.8 days at the human dose. Thus, the human bone marrow is already impaired on the day 3. Production of B-cells and other immunity functions are weakened. This is consistent with the clinical trials’ results: the patients given Molnupiravir within the first 3 days from symptoms onset had much worse outcomes than the patients given Molnupiravir later. This is because the bone marrow has already done its job creating B-cells to fight SARS-COV-2 after 3 days from symptoms onset, typically.

Bone marrow toxicity of Molnupiravir, in the Merck’s own brief:

Bone marrow/hematopoietic findings 

In the 1-month repeat-dose toxicity study in dogs (doses of 6, 17, and 50 mg/kg/day), mild dose-related hematologic findings affecting all cell lines were observed following 7 days of dosing. 

Continue reading Molnupiravir Poisons Bone Marrow when it is Needed Most →

Molnupiravir worsens COVID-19, re-analysis shows

healthcare, ,

My preprint Re-Analysis of Molnupiravir Trials, Phase II/III is published by the TrialSite News. It is paywalled, but a free copy is here Molnupiravir-Trial-2.pdf.

The main observation is that the earlier patients are started on Molnupiravir, the worse their outcomes tend to be. Also, the Molnupiravir arm of the the Part 2 Trial had 33% higher risk of hospitalization or death, compared with the placebo arm. Conclusion: Molnupiravir is not effective for COVID-19. Continue reading Molnupiravir worsens COVID-19, re-analysis shows →

Some Spike Mutations of B.1.1.529 were Observed in Molnupiravir Patients

healthcare, ,

Some spike mutations of the new variant of concern B.1.1.529 were observed in patients receiving Molnupiravir with the frequency >5%: del143, del144, del145, N501Y, and P681H.

Two of them (del143 and del145) were not in any prior VOC, and the other two were only in Alpha.

Molnupiravir has been authorized in the UK. Some countries started using it without authorizing. Also, significant quantities of Molnupiravir have been manufactured and shipped all over the world. Continue reading Some Spike Mutations of B.1.1.529 were Observed in Molnupiravir Patients →

Molnupiravir: mutagenic, carcinogenic, authorized in the UK

healthcare, preprint,

Published in TrialSite News on November 6, 2021 (behind paywall). Download PDF: Molnupiravir Mutagenic Carcinogenic TSN.pdf

The UK authorization of Molnupiravir for mild/moderate COVID-191 says a lot about the current COVID-19 derangement syndrome. Molnupiravir’s efficacy is marginal, but its mutagenicity and carcinogenicity are real. The tidbits of information published by the UK’s MHRA include bone marrow toxicity discovered in some early trials, something suggested earlier in an article2 on this site. Thus, Molnupiravir is likely to cause leukemia.

The re-analysis of the data in Merck’s press release from October3, suggests that the announced results show much lower efficacy than claimed, even without questioning the conduct of the trial and reporting. Merck’s failure to publish that data is alarming. Merck also failed to disclose the outcomes from patients who were recruited after the cut-off date for the intermediate review.

The UK authorization also reveals that the population in Merck’s trial was younger and less at risk than the general population. When treated with Molnupiravir, the trial population had worse outcome than the comparable general population not treated with Molnupiravir. Continue reading Molnupiravir: mutagenic, carcinogenic, authorized in the UK →